title: Evaluation of primary prophylaxis with granulocyte colony-stimulating factor for epithelial ovarian cancer.
abstract: OBJECTIVE
  Primary prophylaxis with G-CSF has been used to minimize myelosuppression caused by anticancer agents and to avoid severe neutropenia. The authors retrospectively examined the value of primary prophylaxis using granulocyte colony-stimulating factor (G-CSF) for epithelial ovarian cancer.
  
  
  METHODS
  From 2001 to 2010, 105 patients with ovarian cancer receiving chemotherapy in the present hospital were divided into two groups: one received primary prophylaxis with G-CSF and the other did not receive it in compliance with the guidelines for G-CSF usage. The incidence of febrile neutropenia (FN), degree of neutropenia, frequency of G-CSF administration, number of days of hospitalization, progression-free survival (PFS), and overall survival (OS) were evaluated.
  
  
  RESULTS
  Neutrophils decreased almost equally and the length of hospitalization was not significantly lower between the groups. Five-year PFS or OS showed no significant difference either.
  
  
  CONCLUSIONS
  Primary prophylaxis with G-CSF in chemotherapy for epithelial ovarian cancer could be of low significance.
authors.forename: K
authors.initials: K
authors.lastname: Matsui
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: M
authors.initials: M
authors.lastname: Sawada
authors.forename: H
authors.initials: H
authors.lastname: Kuroboshi
authors.forename: H
authors.initials: H
authors.lastname: Tatsumi
authors.forename: T
authors.initials: T
authors.lastname: Yoshioka
authors.forename: M
authors.initials: M
authors.lastname: Akiyama
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Iwasaku
authors.forename: J
authors.initials: J
authors.lastname: Kitawaki
mesh_terms: D000328:Adult; D000368:Aged; D019072:Antibiotic Prophylaxis; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000209:etiology / Q000517:prevention & control; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D016179:Granulocyte Colony-Stimulating Factor